MRVI1-AS1 has been reported to be associated with nasopharyngeal cancer sensitivity to paclitaxel by regulating the Hippo-TAZ signaling pathway [25], which suggests the close association of MRVI1-AS1 with tumor progression to some extent. Here, IRAG1 is linked to nasopharyngeal carcinoma.